---
title: "Neumora Therapeutics posts corporate presentation on neuroscience drug development pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293920823.md"
description: "Neumora Therapeutics released a corporate presentation detailing its neuroscience drug development pipeline, highlighting three lead programs: NMRA-215 (NLRP3 inhibitor for obesity/CV risk), NMRA-511 (V1aR antagonist for Alzheimer's agitation), and NMRA-898 (M4 modulator for schizophrenia). Key milestones include IND submission for NMRA-215 in late 2026, Phase 2 initiation for NMRA-511 by year-end 2026, and Phase 1 data for NMRA-898 in the second half of 2026. Preclinical data showed significant weight loss potential for NMRA-215."
datetime: "2026-07-27T11:03:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293920823.md)
  - [en](https://longbridge.com/en/news/293920823.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293920823.md)
generator: "portal-rs"
---

# Neumora Therapeutics posts corporate presentation on neuroscience drug development pipeline

-   Neumora outlined three lead programs across cardiometabolic, neurodegenerative, neuropsychiatric disease, anchored by NMRA-215, NMRA-511, NMRA-898. \* NMRA-215 NLRP3 inhibitor in obesity/CV risk: IND submission targeted for 4Q 2026; Phase 1 start planned by year-end 2026. \* NMRA-511 V1aR antagonist for agitation in Alzheimer’s disease: multiple-ascending-dose extension data expected 4Q 2026; Phase 2 initiation planned by year-end 2026. \* NMRA-898 M4 modulator for schizophrenia: Phase 1 data expected in 2H 2026. \* Preclinical NMRA-215 data showed up to 19% weight loss as monotherapy; up to 26% when combined with semaglutide. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NMRA.US](https://longbridge.com/en/quote/NMRA.US.md)

## Related News & Research

- [Neumora Therapeutics posts corporate presentation on neuroscience drug development strategy](https://longbridge.com/en/news/295927092.md)
- [Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher](https://longbridge.com/en/news/297402586.md)
- [05:00 ETAbacus Health Solutions Reports Long-Term Weight Loss Maintenance Outcomes, Addressing a Critical Evidence Gap in Obesity Care](https://longbridge.com/en/news/297624826.md)
- [Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance](https://longbridge.com/en/news/297698935.md)
- [Eli Lilly's Taltz-Zepbound Combo Shows Encouraging Results At Week 52](https://longbridge.com/en/news/297510647.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**